ERYTECH Announces Third DSMB Safety Review and Continuation of Its Phase 2b Study in Acute Myeloid Leukemia
ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces that an independent Data and Safety Monitoring Board (DSMB 1 ) completed its third safety assessment of the company’s Phase 2b ENFORCE 1 study in acute myeloid leukemia (AML) and that enrollment will continue until completion.
The ENFORCE 1 study is a multinational, randomized, controlled Phase 2b trial evaluating the efficacy and tolerability of GRASPA in the treatment of newly diagnosed AML patients over 65 years of age and unfit for intensive chemotherapy. The primary endpoint of the study is overall survival (OS) following a recently approved protocol amendment, changing the endpoint from progression free survival (PFS) to OS. OS is considered a more robust endpoint in this indication.
Today, more than 90% out of a total of 123 patients to be treated have been enrolled in the study in over 20 active centers in France, Spain, Finland, Norway and Italy.
Two safety assessments had already been performed by an external DSMB when 30 patients and 60 patients were treated in the study with no safety concerns identified. The third DSMB safety review, now with 105 patients treated, again raised no safety concerns. The DSMB noted that their observations regarding the main endpoints are unlikely to change with the additional patients, although the statistical power should be improved. Based on the DSMB comments, ERYTECH decided to continue enrolment into the trial until completion, which is expected during the first quarter of 2016. Primary results are expected in 2017.
About ERYTECH and ERY-ASP (GRASPA®): www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. ERYTECH has recently announced positive efficacy and safety results from its completed Phase 2/3 pivotal clinical trial in Europe with its lead product candidate, ERY-ASP, also known under the trade name GRASPA®, in children and adults with relapsed or refractory ALL. ERYTECH also has an ongoing Phase 1 clinical trial of ERY-ASP in the United States in adults with newly diagnosed ALL, and a Phase 2 clinical trial in Europe in elderly patients with newly diagnosed AML, each in combination with chemotherapy.
ERY-ASP consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells, from circulating blood plasma.
Every year over 50,000 patients in Europe and the United States are diagnosed with ALL or AML. For about 80% of these patients, mainly adults and relapsing patients, current forms of L-asparaginase cannot be used due to their toxicity or as a result of allergic reactions. ERYTECH believes that the safety and efficacy profile of ERY-ASP/GRASPA®, as observed in its Phase 2/3 pivotal clinical trial, offers an attractive alternative option for the treatment of leukemia patients.
ERYTECH believes that ERY-ASP has the potential as a treatment approach in solid tumors and is conducting a Phase 2 clinical trial in Europe in patients with metastatic pancreatic cancer. In addition to its current product candidates that focus on using encapsulated enzymes to induce tumor starvation, ERYTECH is exploring the use of its platform for developing cancer vaccines and enzyme replacement therapies.
The EMA and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for ERY-ASP/GRASPA for the treatment of ALL, AML and pancreatic cancer. ERYTECH produces ERY-ASP at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for ERY-ASP for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name.
ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the U.S. under an ADR level 1 program (OTC, ticker EYRYY).
This document may contain forward-looking statements and estimates with respect to the financial position, results of operations, business strategy, plans, objectives and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on ERYTECH’s website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.
1 A DSMB is an external committee of independent clinical research experts who review data in ongoing clinical trials with particular attention to safety.
Chairman and CEO
CFO and COO
Tel: +33 4 78 74 44 38
Julien Perez / Emmanuel Huynh
Tel: +33 1 44 71 98 52
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
FLIR Launches Thermal Traffic Sensor for Vehicle-to-Everything Communication20.3.2018 07:00 | Pressemelding
FLIR Systems, Inc. (NASDAQ: FLIR) today announced the launch of the FLIR ThermiCam™ V2X, a thermal traffic sensor for the emerging vehicle-to-everything (V2X) technology market. The FLIR V2X-enabled traffic sensor for urban traffic will allow vehicles and traffic infrastructure to communicate and share data in a system that aims to improve motorist, pedestrian, and bicyclist safety and efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005416/en/ FLIR ThermiCam V2X thermal traffic sensor designed for the emerging vehicle-to-everything (V2X) technology market will communicate with V2X-equipped vehicles. (Photo: Business Wire) V2X technology is an emerging crash avoidance system that relies on the communication of information between nearby vehicles and traffic infrastructure to warn drivers about potentially dangerous situations. In a V2X system, both the vehicles and infrastructure have communication units inst
Shopping on Instagram Goes Global with Shopify20.3.2018 06:00 | Pressemelding
Shopify Inc. (NYSE: SHOP) (TSX: SHOP), the leading multi-channel commerce platform, today announces its expanded integration with Instagram. The “shopping on Instagram” feature that allows businesses to tag products in Instagram posts is now enabled for merchants in eight additional markets: UK, Australia, Canada, Germany, France, Italy, Spain and Brazil. This strategic expansion unlocks potential for Shopify’s merchants to sell to Instagram users all over the world. Instagram, a fun, popular photo-sharing app for mobile devices, is a great venue for Shopify’s hundreds of thousands of merchants in categories such as fashion, jewelry, beauty, furniture and home decor to grow their customer base in a meaningful way. Riding on the successes from the earlier rollout for Shopify’s U.S. merchants, the expanded integration will allow shoppers all over the world to experience this unique commerce feature on Instagram. With the objective of helping our merchants reach more shoppers around the w
Oxford Nanopore Announces £100 Million ($140M) Fundraising from Global Investors20.3.2018 06:00 | Pressemelding
Oxford Nanopore Technologies Ltd, the company behind the only portable real-time DNA/RNA sequencer, MinION, has raised £100M ($140M) in new investment. Funds were raised from global investors including GIC (Singapore), China Construction Bank International (CCBI, China), Hostplus (Australia), and existing investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180319006158/en/ Oxford Nanopore’s novel DNA/RNA sequencing technology: the portable MinION is now being joined by other formats including high-throughput, on-demand PromethION and single-test Flongle (Graphic: Business Wire) The funds will be used to support the Company’s next phase of commercial expansion. This includes a new high-volume, high-tech manufacturing facility in Oxford to meet accelerating demand for Oxford Nanopore’s sequencing technology, and growth of the commercial team that already serves more than 70 countries. The funds raised will also support R
Milrem Robotics is Developing a Firefighting and Search and Rescue UGV20.3.2018 06:00 | Pressemelding
Known mostly for their smart warfare systems – Milrem Robotics – is entering the commercial market with its firefighting and search and rescue unmanned ground vehicle being developed together with rescue services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180319005756/en/ Known mostly for their smart warfare systems - Milrem Robotics - is entering the commercial market with its firefighting and search and rescue unmanned ground vehicle being developed together with rescue services. (Photo: Business Wire) The UGV known as Multiscope Rescue can be equipped with firefighting equipment such as a water tank and a remotely controlled water cannon. It can reach areas that are unreachable by human personnel or too dangerous for firefighters to go into like tunnels or other structures that may collapse at any time. The search and rescue unit can also be equipped with thermal cameras and powerful lights to find missing people in
RagingWire Opens New VA3 Data Center and Ashburn Data Center Campus in the Heart of Famed "Data Center Alley"20.3.2018 02:09 | Pressemelding
RagingWire Data Centers, Inc., the premier data center provider in North America and its parent company NTT Communications (NTT Com), the information and communications technology (ICT) solutions and international communications business within the NTT Group (TOKYO: 9432), today announced the opening of its new Ashburn VA3 Data Center, a state-of-the-art facility with 245,000 square feet of space and 16 megawatts of critical power, located on RagingWire’s new Ashburn Data Center Campus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180319006380/en/ RagingWire new Ashburn VA3 Data Center (Graphic: Business Wire) “With 16 megawatts available today at the new VA3 Data Center and massive scalability in our new Ashburn Data Center Campus, RagingWire has become the destination of choice for hyperscale, high-growth customers in the top data center market in the world,” said RagingWire President and CEO Doug Adams. “Plus our global
FAA Approves AerTrakTM to Comply with Automatic Dependent Surveillance-Broadcast (ADS-B) Operations Mandate19.3.2018 18:19 | Pressemelding
The Federal Aviation Administration (FAA) has issued a Supplemental Type Certificate (STC) for installation of AerSale®’s AerTrak™ system on Boeing 737 NG series aircraft (ST04009NY), to comply with the Automatic Dependent Surveillance-Broadcast (ADS-B) Operations rule, a critical part of the agency’s Next Generation Air Transportation System (NextGen). Beginning January 1, 2020, the FAA has mandated that aircraft operating in airspace defined by 14 CFR § 91.225 must be equipped with an ADS-B Out system that meets the minimum performance requirements of 14 CFR § 91.227. ADS-B provides enhanced navigational accuracy using precise tracking via global positioning satellite (GPS) signals. Reducing risk and improving safety, the technology increases navigational coverage, especially in remote areas beyond radar range. Additionally, ADS-B enables more direct flight plans, thereby saving time, costs, and reducing emissions. “AerTrak is a cost-effective ADS-B Out solution for operators of Boei